My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 759

    1.

    Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease.

    Palmer AJ, Annemans L, Roze S, Lamotte M, Lapuerta P, Chen R, Gabriel S, Carita P, Rodby RA, de Zeeuw D, Parving HH.

    Diabetes Care. 2004 Aug;27(8):1897-903.PMID: 15277414 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.

    Palmer AJ, Valentine WJ, Tucker DM, Ray JA, Roze S, Annemans L, Lapuerta P, Chen R, Gabriel S, Carita P, Rodby RA, de Zeeuw D, Parving HH, Laville M.

    Curr Med Res Opin. 2006 Nov;22(11):2095-100.PMID: 17076969 [PubMed - indexed for MEDLINE]Related articles

    3.

    Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland.

    Palmer AJ, Roze S, Valentine WJ, Ray JA, Frei A, Burnier M, Hess B, Spinas GA, Brändle M.

    Swiss Med Wkly. 2006 May 27;136(21-22):346-52.PMID: 16779715 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis.

    Palmer AJ, Valentine WJ, Ray JA.

    Int J Clin Pract. 2007 Oct;61(10):1626-33. Review.PMID: 17877649 [PubMed - indexed for MEDLINE]Related articles

    5.

    [Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy]

    Palmer AJ, Roze S, Rodby RA, Valentine WJ, Ritz E, Lehnert H.

    Dtsch Med Wochenschr. 2006 Aug 4;131(31-32):1721-6. German. PMID: 16868875 [PubMed - indexed for MEDLINE]Related articles

    6.

    Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective.

    Coyle D, Rodby R, Soroka S, Levin A, Muirhead N, de Cotret PR, Chen R, Palmer A.

    Clin Ther. 2007 Jul;29(7):1508-23.PMID: 17825702 [PubMed - indexed for MEDLINE]Related articles

    7.

    Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria.

    Palmer AJ, Annemans L, Roze S, Lapuerta P, Chen R, Gabriel S, Carita P, Rodby RA, de Zeeuw D, Parving HH, De Alvaro F.

    Kidney Int Suppl. 2005 Jan;(93):S52-4.PMID: 15613069 [PubMed - indexed for MEDLINE]Related articles

    8.

    An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings.

    Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Cordonnier DJ.

    Nephrol Dial Transplant. 2003 Oct;18(10):2059-66.PMID: 13679481 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    [Cost-efectiveness of Ibersartan in type II diabetic nephropathy with hypertension. A Spanish perspective]

    Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, de Alvaro F; Grupo de Estudio Colaborativo IDNT.

    Nefrologia. 2004;24(3):231-8. Spanish. PMID: 15283313 [PubMed - indexed for MEDLINE]Related articles

    10.

    Health economics studies assessing irbesartan use in patients with hypertension, type 2 diabetes, and microalbuminuria.

    Palmer AJ, Rodby RA.

    Kidney Int Suppl. 2004 Nov;(92):S118-20. Review.PMID: 15485404 [PubMed - indexed for MEDLINE]Related articles

    11.

    [Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension]

    Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Ritz E.

    Dtsch Med Wochenschr. 2004 Jan 2;129(1-2):13-8. German. PMID: 14703575 [PubMed - indexed for MEDLINE]Related articles

    12.

    Treatment of diabetic nephropathy with angiotensin II receptor antagonist.

    Lewis EJ, Lewis JB.

    Clin Exp Nephrol. 2003 Mar;7(1):1-8. Review.PMID: 14586737 [PubMed - indexed for MEDLINE]Related articles

    13.

    An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting.

    Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Bilous RW.

    J Hum Hypertens. 2004 Oct;18(10):733-8.PMID: 15116142 [PubMed - indexed for MEDLINE]Related articles

    14.

    [Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland]

    Frei A, Palmer AJ, Burnier M, Hess B.

    Praxis (Bern 1994). 2006 Mar 15;95(11):401-8. German. PMID: 16570646 [PubMed - indexed for MEDLINE]Related articles

    15.

    Economic evaluation of the use of irbesartan and amlodipine in the treatment of diabetic nephropathy in patients with hypertension in Canada.

    Coyle D, Rodby RA.

    Can J Cardiol. 2004 Jan;20(1):71-9.PMID: 14968145 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    An Asian regional analysis of cost-effectiveness of early irbesartan treatment versus conventional antihypertensive, late amlodipine, and late irbesartan treatments in patients with type 2 diabetes, hypertension, and nephropathy.

    Annemans L, Demarteau N, Hu S, Lee TJ, Morad Z, Supaporn T, Yang WC, Palmer AJ.

    Value Health. 2008 May-Jun;11(3):354-64. Epub 2007 Sep 21.PMID: 17888064 [PubMed - indexed for MEDLINE]Related articles

    17.

    Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.

    Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ; Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group.

    Ann Intern Med. 2003 Apr 1;138(7):542-9.PMID: 12667024 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy.

    Rodby RA, Chiou CF, Borenstein J, Smitten A, Sengupta N, Palmer AJ, Roze S, Annemans L, Simon TA, Chen RS, Lewis EJ; Collaborative Study Group.

    Clin Ther. 2003 Jul;25(7):2102-19.PMID: 12946554 [PubMed - indexed for MEDLINE]Related articles

    19.

    Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis.

    Palmer AJ, Valentine WJ, Ray JA, Roze S, Muszbek N.

    Eur J Health Econ. 2007 Jun;8(2):161-8. Epub 2007 Jan 20.PMID: 17237927 [PubMed - indexed for MEDLINE]Related articles

    20.

    The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.

    Rodby RA, Rohde RD, Clarke WR, Hunsicker LG, Anzalone DA, Atkins RC, Ritz E, Lewis EJ.

    Nephrol Dial Transplant. 2000 Apr;15(4):487-97.PMID: 10727543 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity